Amicus Therapeutics, Inc. (FOLD)

$10.82

+0.21

(+1.98%)

Market is closed - opens 7 PM, 23 Apr 2024

Insights on Amicus Therapeutics, Inc.

  • Increasing Revenue

    Revenue is up for the last 4 quarters, 86.27M → 115.08M (in $), with an average increase of 9.2% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -21.57M → -33.84M (in $), with an average decrease of 56.9% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 42.1% return, outperforming this stock by 49.4%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 231.4% return, outperforming this stock by 225.4%

Performance

  • $10.66
    $10.91
    $10.82
    downward going graph

    1.48%

    Downside

    Day's Volatility :2.29%

    Upside

    0.82%

    downward going graph
  • $9.70
    $14.57
    $10.82
    downward going graph

    10.35%

    Downside

    52 Weeks Volatility :33.42%

    Upside

    25.74%

    downward going graph

Returns

PeriodAmicus Therapeutics, Inc.Sector (Health Care)Index (Russel 2000)
3 Months
-13.16%
-0.7%
0.0%
6 Months
-1.94%
9.2%
0.0%
1 Year
-5.83%
3.5%
-1.3%
3 Years
7.5%
12.3%
-22.1%

Highlights

Market Capitalization
3.1B
Book Value
$0.55
Earnings Per Share (EPS)
-0.51
PEG Ratio
-0.18
Wall Street Target Price
18.75
Profit Margin
-37.96%
Operating Margin TTM
-3.21%
Return On Assets TTM
-6.12%
Return On Equity TTM
-107.04%
Revenue TTM
399.4M
Revenue Per Share TTM
1.35
Quarterly Revenue Growth YOY
30.599999999999998%
Gross Profit TTM
290.6M
EBITDA
-65.6M
Diluted Eps TTM
-0.51
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
0.0
EPS Estimate Next Year
0.39
EPS Estimate Current Quarter
-0.06
EPS Estimate Next Quarter
-0.05

Analyst Recommendation

Buy
    66%Buy
    33%Hold
    0
    0%Sell
Based on 18 Wall street analysts offering stock ratings for Amicus Therapeutics, Inc.(by analysts ranked 0 to 5 stars)
Based on 18 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
12
12
12
Hold
6
6
6
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 73.29%

Current $10.82
Target $18.75

Company Financials

FY18Y/Y Change
Revenue
91.2M
↑ 147.08%
Net Income
-349.0M
↑ 22.88%
Net Profit Margin
-382.48%
↑ 386.55%
FY19Y/Y Change
Revenue
182.2M
↑ 99.72%
Net Income
-356.4M
↑ 2.12%
Net Profit Margin
-195.56%
↑ 186.92%
FY20Y/Y Change
Revenue
260.9M
↑ 43.16%
Net Income
-276.9M
↓ 22.32%
Net Profit Margin
-106.12%
↑ 89.44%
FY21Y/Y Change
Revenue
305.5M
↑ 17.11%
Net Income
-250.5M
↓ 9.53%
Net Profit Margin
-81.98%
↑ 24.14%
FY22Y/Y Change
Revenue
329.2M
↑ 7.76%
Net Income
-236.6M
↓ 5.55%
Net Profit Margin
-71.85%
↑ 10.13%
FY23Y/Y Change
Revenue
399.4M
↑ 21.3%
Net Income
-151.6M
↓ 35.92%
Net Profit Margin
-37.96%
↑ 33.89%
Q3 FY22Q/Q Change
Revenue
81.7M
↑ 1.19%
Net Income
-33.3M
↓ 46.45%
Net Profit Margin
-40.75%
↑ 36.24%
Q4 FY22Q/Q Change
Revenue
88.1M
↑ 7.84%
Net Income
-55.9M
↑ 67.83%
Net Profit Margin
-63.41%
↓ 22.66%
Q1 FY23Q/Q Change
Revenue
86.3M
↓ 2.07%
Net Income
-52.9M
↓ 5.25%
Net Profit Margin
-61.36%
↑ 2.05%
Q2 FY23Q/Q Change
Revenue
94.5M
↑ 9.54%
Net Income
-43.2M
↓ 18.33%
Net Profit Margin
-45.75%
↑ 15.61%
Q3 FY23Q/Q Change
Revenue
103.5M
↑ 9.52%
Net Income
-21.6M
↓ 50.09%
Net Profit Margin
-20.85%
↑ 24.9%
Q4 FY23Q/Q Change
Revenue
115.1M
↑ 11.19%
Net Income
-33.8M
↑ 56.85%
Net Profit Margin
-29.41%
↓ 8.56%
FY18Y/Y Change
Total Assets
790.0M
↑ 25.98%
Total Liabilities
447.0M
↑ 63.05%
FY19Y/Y Change
Total Assets
850.2M
↑ 7.63%
Total Liabilities
373.8M
↓ 16.39%
FY20Y/Y Change
Total Assets
886.5M
↑ 4.27%
Total Liabilities
600.1M
↑ 60.56%
FY21Y/Y Change
Total Assets
905.1M
↑ 2.1%
Total Liabilities
597.8M
↓ 0.39%
FY22Y/Y Change
Total Assets
724.2M
↓ 19.99%
Total Liabilities
601.1M
↑ 0.56%
FY23Y/Y Change
Total Assets
777.9M
↑ 7.42%
Total Liabilities
617.7M
↑ 2.76%
Q3 FY22Q/Q Change
Total Assets
759.5M
↓ 5.13%
Total Liabilities
627.0M
↓ 0.03%
Q4 FY22Q/Q Change
Total Assets
724.2M
↓ 4.66%
Total Liabilities
601.1M
↓ 4.12%
Q1 FY23Q/Q Change
Total Assets
700.5M
↓ 3.27%
Total Liabilities
597.9M
↓ 0.53%
Q2 FY23Q/Q Change
Total Assets
730.1M
↑ 4.22%
Total Liabilities
618.5M
↑ 3.44%
Q3 FY23Q/Q Change
Total Assets
764.1M
↑ 4.66%
Total Liabilities
630.8M
↑ 1.99%
Q4 FY23Q/Q Change
Total Assets
777.9M
↑ 1.81%
Total Liabilities
617.7M
↓ 2.08%
FY18Y/Y Change
Operating Cash Flow
-300.0M
↑ 39.2%
Investing Cash Flow
-121.2M
↓ 29.22%
Financing Cash Flow
450.8M
↑ 82.18%
FY19Y/Y Change
Operating Cash Flow
-250.4M
↓ 16.52%
Investing Cash Flow
95.2M
↓ 178.51%
Financing Cash Flow
217.5M
↓ 51.75%
FY20Y/Y Change
Operating Cash Flow
-233.3M
↓ 6.84%
Investing Cash Flow
-13.6M
↓ 114.27%
Financing Cash Flow
262.9M
↑ 20.85%
FY21Y/Y Change
Operating Cash Flow
-202.5M
↓ 13.2%
Investing Cash Flow
78.8M
↓ 680.02%
Financing Cash Flow
212.1M
↓ 19.32%
FY22Y/Y Change
Operating Cash Flow
-166.6M
↓ 17.74%
Investing Cash Flow
92.3M
↑ 17.21%
Financing Cash Flow
-7.5M
↓ 103.52%
Q3 FY22Q/Q Change
Operating Cash Flow
-11.6M
↓ 26.71%
Investing Cash Flow
74.5M
↑ 183.41%
Financing Cash Flow
-559.0K
↓ 180.66%
Q4 FY22Q/Q Change
Operating Cash Flow
-80.8M
↑ 594.75%
Investing Cash Flow
-66.7M
↓ 189.52%
Financing Cash Flow
557.0K
↓ 199.64%
Q1 FY23Q/Q Change
Operating Cash Flow
-18.1M
↓ 77.63%
Investing Cash Flow
36.3M
↓ 154.35%
Financing Cash Flow
-7.8M
↓ 1504.85%
Q2 FY23Q/Q Change
Operating Cash Flow
-16.1M
↓ 10.71%
Investing Cash Flow
50.0M
↑ 37.91%
Financing Cash Flow
23.7M
↓ 402.53%
Q3 FY23Q/Q Change
Operating Cash Flow
-38.3M
↑ 137.69%
Investing Cash Flow
35.8M
↓ 28.47%
Financing Cash Flow
37.6M
↑ 58.91%

Technicals Summary

Sell

Neutral

Buy

Amicus Therapeutics, Inc. is currently in a neutral trading position according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Amicus Therapeutics, Inc.
Amicus Therapeutics, Inc.
-6.24%
-1.94%
-5.83%
7.5%
-18.59%
Moderna, Inc.
Moderna, Inc.
-3.81%
28.95%
-26.59%
-39.67%
329.16%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-7.28%
12.73%
12.52%
82.86%
168.48%
Novo Nordisk A/s
Novo Nordisk A/s
-4.7%
26.35%
43.96%
230.98%
410.23%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-3.87%
7.24%
20.15%
82.55%
128.04%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Amicus Therapeutics, Inc.
Amicus Therapeutics, Inc.
NA
NA
-0.18
0.0
-1.07
-0.06
NA
0.55
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.22
-0.29
-0.12
NA
36.27
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
25.72
25.72
1.46
45.22
0.16
0.08
NA
242.47
Novo Nordisk A/s
Novo Nordisk A/s
46.32
46.32
2.4
3.33
0.88
0.23
0.01
23.9
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
28.33
28.33
0.53
16.77
0.23
0.13
NA
68.22
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Amicus Therapeutics, Inc.
Amicus Therapeutics, Inc.
Buy
$3.1B
-18.59%
NA
-37.96%
Moderna, Inc.
Moderna, Inc.
Buy
$38.8B
329.16%
24.73
-68.84%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$98.1B
168.48%
25.72
30.14%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$550.4B
410.23%
46.32
36.03%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$101.7B
128.04%
28.33
36.68%

Institutional Holdings

  • Vanguard Group Inc

    9.65%
  • Perceptive Advisors LLC

    9.50%
  • venBio Select Advisor LLC

    9.28%
  • BlackRock Inc

    7.78%
  • JPMorgan Chase & Co

    6.04%
  • Redmile Group, LLC

    5.74%

Corporate Announcements

  • Amicus Therapeutics, Inc. Earnings

    Amicus Therapeutics, Inc.’s price-to-earnings ratio stands at None

    Read More

Company Information

amicus therapeutics is a global, patient-centric biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare metabolic diseases. we have a unique set of platform technologies and medicines in development for patients living with the lysosomal storage disorders fabry disease and pompe disease and we are committed to advancing and expanding a robust pipeline of cutting-edge, first- or best-in-class medicines for these and other rare diseases. the needs of patients in the rare disease community are at the center of our inventive science, our commercial organization, and our clinical programs. our goal throughout all levels of the organization is to make a meaningful difference in the lives of these patients and their caregivers. several opportunities are available to join our team as we build a leading global biotechnology company focused on rare metabolic diseases. our amicus footprint spans 27 countries including our g

Organization
Amicus Therapeutics, Inc.
Employees
517
CEO
Mr. Bradley L. Campbell M.B.A.
Industry
Health Technology

FAQs